Drugs / Methylenblue
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00917202 | — | malaria | Heidelberg University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00545935 Comparator | Jul → Oct 2007 | malaria | Heidelberg University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Methylenblue | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00545935 ↗ |
| Route | Oral | “will receive orally twice daily 390 mg MB” NCT00917202 ↗ |